Studies back drugs for gout and colitis

12/8/2005 | Wall Street Journal, The

The studies cited TAP Pharmaceutical Products' febuxostat, which is awaiting U.S. approval, as showing promise against gout while Centocor's infliximab was shown to sharply reduce bloody diarrhea, abdominal cramps and other symptoms associated with ulcerative colitis. Infliximab is sold as Remicade for arthritis and Crohn's disease.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA